Welcome to the Kids' Library!

Search for books, movies, music, magazines, and more.

Back to Search Results

Available items only

Previous Record Next Record

Author

Donghi, Monica, author.

Title Patent strategy in pharmaceutical industry : are additional patents valuable? / Monica Donghi.

Publication Info.

Baden-Baden : Nomos, 2014.

Connect to
Connect to https://pittstate.idm.oclc.org/login?url=https://www.jstor.org/stable/10.2307/j.ctv941vfr

Copies

Location	Call No.	OPAC Message	Status
Axe JSTOR Open Ebooks	Electronic Book	---	Available

Edition	1. Auflage.
Description	1 electronic resource (84 pages ).
	text txt rdacontent
	computer c rdamedia
	online resource cr rdacarrier
	data file
Series	MIPLC studies ; volume 20
	MIPLC studies ; volume 20.
Note	Originally presented as author's thesis (LL.M.)--Munich Intellectual Property Law Center, 2012.
Bibliography	Includes bibliographical references (pages 77-84).
Note	Description based on print version record; resource not viewed.
Contents	Acronyms and Abbreviations; I. Introduction; II. Background; A. Pharmaceutical Industry -- The Development of a New Drug.; B. New Drug Approval Regulations; C. Generic Drugs Approval.; III. Case Studies-Facts; A. Taxotere; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Derivatives; 3. Use of Procedural Provisions: Supplementary Protection Certificates (SPCs)/Patent Term Extension; 4. Conclusion; B. Xalatan; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Delivery Devices.
	F) Packaged Product3. Use of Procedural Provisions; a) Divisional of Basic Patent; b) Supplementary Protection; 4. Conclusion; IV. Discussion; A. Lifecycle Management: Criticism and Supports; B. Further Filing Strategy: Commercial Value; 1. Innovation Tracks; a) Formulations; b) Combinations; c) Process; d) New Uses; e) Delivery Devices; 2. Xalatan SPC Request: a Case for Competition Law?; C. Patent Strategy and Innovation; D. Summary: Taxotere v Xalatan; E. Conclusion and Suggestions; V. Final Remarks; List of works cited; Periodical Materials in English; Periodical Material in German.
	Non Periodical MaterialTable of books; Table of Cases; European Union; EPO Board of Appeal; France; Germany; Italy; United Kingdom; United States; Statutes; Speeches and Reports; Press release; Others.
Summary	Dieses Buch untersucht die Lifecycle-Management-Strategien, die von Pharma-Unternehmen eingesetzt werden, um den Wert ihres Produktportfolios zu maximieren. Solche Strategien werden manchmal von Generika-Unternehmen als "evergreening" bezeichnet. Die Analyse erfolgt anhand zwei zufällig ausgewählter "Blockbuster"--Medikamente, Taxotere und Xalatan und konzentriert sich auf zwei dieser Strategien, nämlich die Produktverbesserung und die Produktlinienerweiterung. Reihe Munich Intellectual Property Law Center - MIPLC - Band 20.
Language	English.
Subject	Drugs -- Patents -- Economic aspects -- European Union countries.
	Patent medicines -- Law and legislation -- European Union countries.
	Patent medicines -- European Union countries -- Case studies.
	Drugs -- Patents.
	Médicaments -- Brevets d'invention.
	Médicaments -- Brevets d'invention -- Aspect économique -- Pays de l'Union européenne.
	Spécialités pharmaceutiques -- Pays de l'Union européenne -- Études de cas.
	LAW -- Commercial -- General.
	Patent medicines
	Patent medicines -- Law and legislation
	European Union countries
Indexed Term	Markenrecht
	Urheberrecht / Gewerblicher Rechtsschutz und Medienrecht
	Gewerblicher Rechtsschutz
Genre/Form	Electronic books.
	Case studies
Other Form:	Print version: Patent strategy in pharmaceutical industry Baden-Baden : Nomos, 2014. 9783848709915 (DLC) 2015372690
ISBN	3848709910
	9783848709915
	9783845251288
	384525128X
Standard No.	AU@ 000056062506
	AU@ 000062534616
	DEBSZ 431647895